The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury

Status:Active, not recruiting
Conditions:Renal Impairment / Chronic Kidney Disease, Hospital
Therapuetic Areas:Nephrology / Urology, Other
Age Range:18 - Any
Start Date:December 2010
End Date:December 2021

Use our guide to learn which trials are right for you!

The primary objective is to safely determine if the investigators can identify the severity
of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled the
investigators will draw blood and urine for novel and standard biomarkers. The investigators
are attempting to determine if these biomarkers can forecast the course of AKI (need for
dialysis, death and renal recovery). The investigators seek to determine how well physicians
caring for those with AKI can predict the clinical course compared to these novel biomarkers
of AKI and if there is an association between clinical course and 3 year patient outcomes.

AKI is a very common disease in the setting of critical illness and carries an extremely high
morbidity and mortality rate (over 50%). Currently there are no FDA approved therapeutic
agents for the treatment of AKI. There is limited prospective evidence to guide nephrologists
in terms of which patients will progress to more severe AKI in the setting of early AKI.
Similarly, there is no evidence to guide nephrologists in terms of which patients will
completely recover their renal function after AKI. Thus we need to know very early in the
course of AKI which patients will progress and go on to require renal replacement therapy
(RRT). Additionally we will investigating the long term patient outcomes, 2-3 years after the
index AKI admission.

Inclusion Criteria:

1. 18 yrs or older

2. increase in serum creatinine of 0.3 mg/dl within 48 hours or an increase of greater
than or equal to 150% from baseline or sustained oliguria (UOP < 0.5 cc/kg/hr for 6
hours with the last 48hours)

3. written informed consent

4. patients with an indwelling bladder catheter

Exclusion Criteria:

1. Voluntary refusal

2. Patients with advanced chronic kidney disease - as defined by a baseline glomerular
filtration rate (GFR) < 30 ml/min (MDRD)

3. history of renal transplant

4. Pregnant patients

5. Allergy / Sensitivity to Loop diuretics (furosemide)

6. Pre-renal AKI

- defined by a Fractional Excretion of Sodium (FENa) of < 1% and no urinary casts

- under-resuscitated as per the treating clinical team

- active bleed

7. Post renal AKI

- evidence of hydro-ureter

- clinical scenario wherein obstruction is considered a likely possibility
We found this trial at
Washington, District of Columbia 20052
Phone: 301-806-7282
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
Phone: 773-702-4842
University of Chicago One of the world's premier academic and research institutions, the University of...
Chicago, IL
Click here to add this to my saved trials
Baltimore, Maryland 21231
Phone: 410-955-5268
Baltimore, MD
Click here to add this to my saved trials
San Francisco, California 94143
Phone: 415-502-7998
San Francisco, CA
Click here to add this to my saved trials